$39.23
7.43% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

PTC Therapeutics, Inc. Stock price

$39.23
+1.67 4.45% 1M
+5.57 16.55% 6M
+11.67 42.34% YTD
+18.46 88.88% 1Y
+0.39 1.00% 3Y
-4.46 10.21% 5Y
+0.04 0.10% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-3.15 7.43%
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

Key metrics

Market capitalization $3.27b
Enterprise Value $2.66b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.95
P/S ratio (TTM) P/S ratio 3.63
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.84%
Revenue (TTM) Revenue $900.66m
EBIT (operating result TTM) EBIT $-127.76m
Free Cash Flow (TTM) Free Cash Flow $-186.27m
Cash position $1.01b
EPS (TTM) EPS $-5.94
P/E forward negative
P/S forward 4.21
EV/Sales forward 3.42
Short interest 9.89%
Show more

Is PTC Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

PTC Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a PTC Therapeutics, Inc. forecast:

7x Buy
44%
6x Hold
38%
3x Sell
19%

Analyst Opinions

16 Analysts have issued a PTC Therapeutics, Inc. forecast:

Buy
44%
Hold
38%
Sell
19%

Financial data from PTC Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
901 901
13% 13%
100%
- Direct Costs 205 205
10% 10%
23%
696 696
22% 22%
77%
- Selling and Administrative Expenses 143 143
1% 1%
16%
- Research and Development Expense 531 531
28% 28%
59%
22 22
107% 107%
2%
- Depreciation and Amortization 150 150
27% 27%
17%
EBIT (Operating Income) EBIT -128 -128
75% 75%
-14%
Net Profit -453 -453
29% 29%
-50%

In millions USD.

Don't miss a Thing! We will send you all news about PTC Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PTC Therapeutics, Inc. Stock News

Positive
Reuters
2 days ago
The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wednesday.
Neutral
PRNewsWire
2 days ago
- First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children and adults - - PTC pioneers new approach for CNS drug delivery - WARREN, N.J., Nov. 13, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy ...
Neutral
Seeking Alpha
8 days ago
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Rick Bienkowski - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jeffe...
More PTC Therapeutics, Inc. News

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Head office United States
CEO Matthew Klein
Employees 995
Founded 1998
Website www.ptcbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today